A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
NCT ID: NCT03374085
Last Updated: 2024-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
201 participants
INTERVENTIONAL
2018-02-06
2028-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
All eligible subjects must be previously treated with at least 3 prior regimens including lenalidomide, pomalidomide, a proteasome inhibitor and an anti-CD38 antibody and be refractory to their last line of therapy.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Administration of CC-92480 in combination with dexamethasone
Part 1: Escalating doses of CC-92480 plus a fixed dose of dexamethasone Part 2: RP2D of CC-92480 in combination with dexamethasone
CC-92480
CC-92480
Dexamethasone
Dexamethasone
Administration of CC-92480 monotherapy
Escalating doses of CC-92480 Monotherapy administered according to different dosing schedules
CC-92480
CC-92480
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CC-92480
CC-92480
Dexamethasone
Dexamethasone
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
5. Subjects must have a documented diagnosis of MM and measurable disease at enrollment. Measurable disease is defined as:
* M-protein quantities ≥ 0.5 g/dL by sPEP or
* ≥ 200 mg/24 hour urine collection by uPEP or
* Serum FLC levels \> 100 mg/L (milligrams/liter) involved light chain and an abnormal kappa/lambda (κ/λ) ratio in subjects without measurable serum or urine M-protein or
* For subjects with immunoglobulin class A (IgA), myeloma whose disease can only be reliably measured by quantitative immunoglobulin measurement, a serum IgA level ≥ 0.50 g/dL.
6. All subjects must have:
* Received at least 3 prior anti-myeloma regimens including at least 2 consecutive cycles of lenalidomide, pomalidomide, a proteasome inhibitor, a glucocorticoid and a CD38 antibody (note: induction with or without bone marrow transplant and with or without maintenance therapy is considered one regimen).
* Documented disease progression on or within 60 days from the last dose of their last myeloma therapy
* Subjects who had CAR-T therapy as their last myeloma therapy are eligible as long as they have documented disease progression following CAR-T therapy.
* In addition to criteria above (a and b), subjects enrolled in Part 2 must have disease refractory to an immunomodulatory agent (lenalidomide and/or pomalidomide), a glucocorticoid, a proteasome inhibitor, and a CD38 antibody. Refractory is defined as disease that is nonresponsive on therapy (failure to achieve minimal response or development of progressive disease), or progresses within 60 days of last dose.
7. Subjects must have the following laboratory values:
* Absolute neutrophil count (ANC) ≥ 1.25 x 109/L without growth factor support for ≥ 7 days (≥ 14 days for pegfilgrastim). ANC of ≥ 1.00 x 109/L is permitted for the dose expansion cohorts (Part 2).
* Hemoglobin (Hgb) ≥ 8 g/dL.
* Platelets (plt) ≥ 75 x 109/L without transfusion for ≥ 7 days.
* Corrected serum calcium ≤ 13.5 mg/dL (≤ 3.4 mmol/L).
* Creatinine clearance (CrCl) based on Cockcroft-Gault formula ≥ 45 mL/min.
* AST/SGOT and ALT/SGPT ≤ 3.0 x upper limit of normal (ULN).
* Serum bilirubin ≤ 1.5 x ULN or \< 3.0 mg/dL for subjects with documented Gilbert's syndrome.
* Uric acid ≤ 7.5 mg/dL (446 µmol/L).
* PT/INR \< 1.5 x ULN and partial thromboplastin time (PTT) \< 1.5 x ULN, (for subjects not receiving therapeutic anticoagulation).
8. Females of childbearing potential (FCBP) must:
* Have two negative pregnancy tests as verified by the Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after discontinuation of CC-92480. This applies even if the subject practices true abstinence\* from heterosexual contact.
* Either commit to true abstinence\* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, two reliable forms of contraception as defined in the PPP and provided to the subject at the time of informed consent, without interruption, 28 days prior to starting CC-92480, during the study therapy (including during dose interruptions), and for 184 days after the last dose of CC-92480.
Note: A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point and, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).
1. Male subjects must:
Practice true abstinence\* (which must be reviewed on a monthly basis) or agree to use of a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study (even during dose interruptions) and for at least 94 days following CC-92480 last dose in accordance with the PPP provided to the subject at the time of informed consent, even if he has undergone a successful vasectomy.
\* True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and coitus interruptus (withdrawal) are not acceptable methods of contraception.
2. Males must agree to refrain from donating sperm while on CC-92480 for 94 days after the last dose of CC-92480. Females must agree to refrain from donating ova while on CC-92480 for 184 days after last dose.
3. All subjects must agree to refrain from donating blood while on CC-92480 and for 28 days after its discontinuation.
Exclusion Criteria
2. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
3. Subject has any condition that confounds the ability to interpret data from the study.
4. Subject has non-secretory multiple myeloma.
5. Subject has refractory primary multiple myeloma (ie, no history of at least a minor response to a prior treatment regimen).
6. Subject has plasma cell leukemia or active leptomeningeal myelomatosis.
7. Subject has documented, systemic light chain amyloidosis or Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes (POEMS) Syndrome.
8. Subject has immunoglobulin class M (IgM) myeloma.
9. Part 1: Subject has a history of allogeneic bone marrow transplantation. Part 2: Subject has a history of allogeneic bone marrow transplantation within 6 months prior to first dose. Subject should not have ongoing graft-versus-host disease (GVHD) requiring systemic immunosuppression.
10. Subject is undergoing dialysis.
11. Subjects with peripheral neuropathy ≥ Grade 2.
12. Subjects with gastrointestinal disease that may significantly alter the absorption of CC-92480.
13. Subject has impaired cardiac function or clinically significant cardiac disease, including any of the following:
* LVEF \< 45% as determined by ECHO or MUGA scan at Screening.
* Complete left bundle branch, bifascicular block or other clinically significant abnormal electrocardiographic (ECG) finding at Screening.
* A prolongation of QT interval on Screening ECG as defined by repeated demonstration of a QTc interval \>480 milliseconds (ms) using Fridericia's QT correction formula; a history of or current risk factors for Torsades de Pointe (eg, heart failure, hypokalemia, or a family history of Long QT Syndrome); and concurrent administration of medications that prolong the QT/QTc interval.
* Congestive heart failure (New York Heart Association Class III or IV).
* Myocardial infarction ≤6 months prior to starting CC-92480.
* Unstable or poorly controlled angina pectoris, including the Prinzmetal variant of angina pectoris.
14. Concurrent administration of strong CYP3A modulators; concurrent administration of proton-pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, pantoprazole) ≤ 2 weeks prior to starting CC-92480.
15. Subject had prior systemic myeloma treatment with an investigational anti-myeloma agent (eg, anti-PD-1, anti-PD-L1) ≤ 5 half-lives prior to starting CC-92480 (not applicable for subjects who had CAR-T as last prior regimen); subject had prior exposure to approved myeloma therapies (including therapeutic monoclonal antibodies such as anti-CD38 or anti-SLAMF7) ≤ 5 half-lives or within 4 weeks prior to starting CC-92480 whichever is shorter.
16. Subject had major surgery ≤ 2 weeks prior to starting CC-92480. Note: Subjects must have recovered from any clinically significant effects of recent surgery.
17. Subject is a pregnant or nursing female, or intends to become pregnant or donate ova during participation in the study.
18. Subject has known human immunodeficiency virus (HIV) infection.
19. Subject has known active chronic hepatitis B or C virus (HBV/HCV) infection.
20. Subject has a history of concurrent second cancer requiring ongoing systemic treatment.
21. Subjects has a history of prior malignancy other than MM, except if the subject has been free of disease for ≥3 years OR the subject had one of the following noninvasive malignancies treated with curative intent without known recurrence:
* Basal or squamous cell carcinoma of the skin.
* Carcinoma in situ of the cervix or breast.
* Stage 1 bladder cancer.
* Incidental histological findings of localized prostate cancer such as tumor stage 1a or 1b (T1a or T1b) using the Tumor/Node/Metastasis (TNM) classification of malignant tumors OR prostate cancer that has been treated with curative intent.
22. Subject has a history of anaphylaxis to thalidomide, lenalidomide, pomalidomide or dexamethasone.
23. Subject has known or suspected hypersensitivity to the excipients (excipients include silica dimethyl silylate, anhydrous colloidal silicon dioxide, mannitol, fumaric acid and stearic acid) contained in the formulation of CC-92480 or dexamethasone.
24. Subject has undergone either of the following within 14 days of initiating CC-92480:
* Plasmapheresis.
* Radiation therapy other than local therapy for symptomatic relief of MM associated bone lesions.
25. Subject has received immunosuppressive medication within 14 days prior to the first dose of CC-92480. The following are exceptions to this criterion:
* Intranasal, inhaled, topical or local corticosteroid injections (eg, intra-articular injection).
* Systemic corticosteroids at doses that do not exceed 10 mg/day of prednisone or the equivalent.
* Steroids as premedication for hypersensitivity reactions (eg, computed tomography \[CT\] scan premedication).
26. Subject is unable or unwilling to undergo protocol required venous thromboembolism (VTE) prophylaxis.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 103
Duarte, California, United States
Local Institution - 102
Atlanta, Georgia, United States
Local Institution - 105
Boston, Massachusetts, United States
Local Institution - 111
Buffalo, New York, United States
Local Institution - 104
New York, New York, United States
Local Institution - 108
Spartanburg, South Carolina, United States
Local Institution - 101
Nashville, Tennessee, United States
Local Institution - 106
Houston, Texas, United States
Local Institution - 112
Charlottesville, Virginia, United States
Local Institution - 109
Seattle, Washington, United States
Local Institution - 804
Camperdown, New South Wales, Australia
Local Institution - 802
Adelaide, South Australia, Australia
Local Institution - 805
Clayton, Victoria, Australia
Local Institution - 803
Melbourne, Victoria, Australia
Local Institution - 806
Fitzroy, , Australia
Local Institution - 904
Antwerp, , Belgium
Local Institution - 905
Ghent, , Belgium
Local Institution - 901
Leuven, , Belgium
Local Institution - 902
Yvoir, , Belgium
Local Institution - 201
Calgary, Alberta, Canada
Local Institution - 204
London, Ontario, Canada
Local Institution - 205
Ottawa, Ontario, Canada
Local Institution - 202
Toronto, Ontario, Canada
Local Institution - 206
Montreal, Quebec, Canada
Local Institution - 203
Québec, Quebec, Canada
Local Institution - 503
Aarhus N, , Denmark
Local Institution - 501
Copenhagen, , Denmark
Local Institution - 502
Odense, , Denmark
Local Institution - 601
Helsinki, , Finland
Local Institution - 001
Athens, , Greece
Local Institution - 705
Chuo-ku,chiba, , Japan
Local Institution - 703
Fukuoka, , Japan
Local Institution - 704
Kashiwa, , Japan
Local Institution - 702
Kobe, , Japan
Local Institution - 706
Kyoto, , Japan
Local Institution - 701
Okayama, , Japan
Local Institution - 152
Seoul, , South Korea
Local Institution - 150
Seoul, , South Korea
Local Institution - 151
Seoul, , South Korea
Local Institution - 403
Badalona (Barcelona), , Spain
Local Institution - 407
Barcelona, , Spain
Local Institution - 406
Cáceres, , Spain
Local Institution - 404
Madrid, , Spain
Local Institution - 401
Pamplona, , Spain
Local Institution - 409
Pozuelo de Alarcón, , Spain
Local Institution - 402
Salamanca, , Spain
Local Institution - 408
Santander, , Spain
Local Institution - 405
Valencia, , Spain
Local Institution - 304
Plymouth, Devon, United Kingdom
Local Institution - 306
Cardiff, , United Kingdom
Local Institution - 303
London, , United Kingdom
Local Institution - 305
Newcastle upon Tyne, , United Kingdom
Local Institution - 302
Oxford, , United Kingdom
Local Institution - 301
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ, Ramasamy K, Martinez-Lopez J, Quach H, Orlowski RZ, Arnao M, Lonial S, Karanes C, Pawlyn C, Kim K, Oriol A, Berdeja JG, Rodriguez Otero P, Casas-Aviles I, Spirli A, Poon J, Li S, Gong J, Wong L, Lamba M, Pierce DW, Amatangelo M, Peluso T, Maciag P, Katz J, Pourdehnad M, Bahlis NJ; CC-92480-MM-001 Study Investigators. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Sep 14;389(11):1009-1022. doi: 10.1056/NEJMoa2303194. Epub 2023 Aug 30.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1205-3650
Identifier Type: REGISTRY
Identifier Source: secondary_id
2017-001236-19
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CC-92480-MM-001
Identifier Type: -
Identifier Source: org_study_id